News & Updates

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Receipt of the COVID-19 vaccine during the follicular phase of the menstrual cycle leads to changes in cycle length, as reported in a study.

Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.

Treatment with denosumab in people with osteoporosis confers a protective effect against the risk of developing diabetes, according to the results of a propensity score–matched cohort study from Taiwan.

Treatment with diazoxide choline extended-release tablet (DCCR) demonstrates good tolerability and delivers significant improvements in people with Prader-Willi syndrome, a rare, complex genetic neurobehavioral/metabolic disorder, results from an open-label study have shown.

The combination therapy of nivolumab plus cabozantinib (NIVO + CABO) continues to show long-term survival benefits and response rates over sunitinib at 55 months in patients with previously untreated advanced renal cell carcinoma (aRCC), according to updated results of the CheckMate 9ER study presented at ASCO GU 2024.

In young children with multiple food allergies, a treatment course with omalizumab appears to increase tolerance to peanuts and other common food allergens.